Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Warner Chilcott



) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 1.7%. By the end of trading, Warner Chilcott rose $0.22 (1.2%) to $18.76 on average volume. Throughout the day, 7,254,633 shares of Warner Chilcott exchanged hands as compared to its average daily volume of 6,867,300 shares. The stock ranged in a price between $18.31-$18.98 after having opened the day at $18.51 as compared to the previous trading day's close of $18.54. Other companies within the Drugs industry that increased today were:

Savient Pharmaceuticals



), up 28.4%,

Rexahn Pharmaceuticals



), up 20.0%,

Hemispherx Biopharma



), up 15.9% and

Atossa Genetics



), up 13.5%.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Warner Chilcott Public Limited Company, a specialty pharmaceutical company, engages in the development, manufacture, promotion, and franchise of branded pharmaceutical products focusing on the women's healthcare, gastroenterology, urology, and dermatology markets. Warner Chilcott has a market cap of $4.8 billion and is part of the health care sector. The company has a P/E ratio of 13.3, below the S&P 500 P/E ratio of 17.7. Shares are down 2.1% year to date as of the close of trading on Tuesday. Currently there are 6 analysts that rate Warner Chilcott a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Warner Chilcott as a


. Among the primary strengths of the company is its expanding profit margins over time. At the same time, however, we also find weaknesses including weak operating cash flow and a generally disappointing performance in the stock itself.

On the negative front,




), down 23.1%,

Skystar Bio-Pharmaceutical Company



), down 16.9%,




), down 13.2% and




), down 11.6% , were all laggards within the drugs industry with




) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.